154 related articles for article (PubMed ID: 35118240)
1. WT1 peptide-based immunotherapy for refractory thymic epithelial malignancies.
Suzuki M; Hishida T; Asakura K; Asamura H
Mediastinum; 2019; 3():12. PubMed ID: 35118240
[No Abstract] [Full Text] [Related]
2. WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.
Oji Y; Inoue M; Takeda Y; Hosen N; Shintani Y; Kawakami M; Harada T; Murakami Y; Iwai M; Fukuda M; Nishida S; Nakata J; Nakae Y; Takashima S; Shirakata T; Nakajima H; Hasegawa K; Kida H; Kijima T; Morimoto S; Fujiki F; Tsuboi A; Morii E; Morita S; Sakamoto J; Kumanogoh A; Oka Y; Okumura M; Sugiyama H
Int J Cancer; 2018 Jun; 142(11):2375-2382. PubMed ID: 29322496
[TBL] [Abstract][Full Text] [Related]
3. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children.
Sawada A; Inoue M; Kondo O; Yamada-Nakata K; Ishihara T; Kuwae Y; Nishikawa M; Ammori Y; Tsuboi A; Oji Y; Koyama-Sato M; Oka Y; Yasui M; Sugiyama H; Kawa K
Pediatr Blood Cancer; 2016 Feb; 63(2):234-41. PubMed ID: 26469989
[TBL] [Abstract][Full Text] [Related]
5. WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial.
Miyatake T; Ueda Y; Morimoto A; Enomoto T; Nishida S; Shirakata T; Oka Y; Tsuboi A; Oji Y; Hosen N; Nakatsuka S; Morita S; Sakamoto J; Sugiyama H; Kimura T
J Cancer Res Clin Oncol; 2013 Mar; 139(3):457-63. PubMed ID: 23160854
[TBL] [Abstract][Full Text] [Related]
6. "Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further development.
Oka Y; Tsuboi A; Fujiki F; Shirakata T; Nishida S; Hosen N; Nakajima H; Li Z; Kawase I; Oji Y; Sugiyama H
Curr Med Chem; 2008; 15(29):3052-61. PubMed ID: 19075652
[TBL] [Abstract][Full Text] [Related]
7. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.
Oka Y; Tsuboi A; Kawakami M; Elisseeva OA; Nakajima H; Udaka K; Kawase I; Oji Y; Sugiyama H
Curr Med Chem; 2006; 13(20):2345-52. PubMed ID: 16918359
[TBL] [Abstract][Full Text] [Related]
8. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
Oka Y; Tsuboi A; Murakami M; Hirai M; Tominaga N; Nakajima H; Elisseeva OA; Masuda T; Nakano A; Kawakami M; Oji Y; Ikegame K; Hosen N; Udaka K; Yasukawa M; Ogawa H; Kawase I; Sugiyama H
Int J Hematol; 2003 Jul; 78(1):56-61. PubMed ID: 12894852
[TBL] [Abstract][Full Text] [Related]
9. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
Tsuboi A; Oka Y; Osaki T; Kumagai T; Tachibana I; Hayashi S; Murakami M; Nakajima H; Elisseeva OA; Fei W; Masuda T; Yasukawa M; Oji Y; Kawakami M; Hosen N; Ikegame K; Yoshihara S; Udaka K; Nakatsuka S; Aozasa K; Kawase I; Sugiyama H
Microbiol Immunol; 2004; 48(3):175-84. PubMed ID: 15031530
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
11. [WT1 peptide-based immunotherapy].
Sugiyama H
Nihon Rinsho; 2005 Jun; 63(6):1101-9. PubMed ID: 15948398
[TBL] [Abstract][Full Text] [Related]
12. [Cancer antigen WT1-targeting treatment for the malignancies].
Oka Y; Kawase I
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):375-82. PubMed ID: 18974621
[TBL] [Abstract][Full Text] [Related]
13. WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report.
Ohta H; Hashii Y; Yoneda A; Takizawa S; Kusuki S; Tokimasa S; Fukuzawa M; Tsuboi A; Murao A; Oka Y; Oji Y; Aozasa K; Nakatsuka S; Sugiyama H; Ozono K
Pediatr Hematol Oncol; 2009 Jan; 26(1):74-83. PubMed ID: 19206012
[TBL] [Abstract][Full Text] [Related]
14. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
Oka Y; Tsuboi A; Elisseeva OA; Nakajima H; Fujiki F; Kawakami M; Shirakata T; Nishida S; Hosen N; Oji Y; Kawase I; Sugiyama H
ScientificWorldJournal; 2007 May; 7():649-65. PubMed ID: 17619750
[TBL] [Abstract][Full Text] [Related]
15. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
[TBL] [Abstract][Full Text] [Related]
16. WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer.
Shirakata T; Oka Y; Nishida S; Hosen N; Tsuboi A; Oji Y; Murao A; Tanaka H; Nakatsuka S; Inohara H; Sugiyama H
Anticancer Res; 2012 Mar; 32(3):1081-5. PubMed ID: 22399636
[TBL] [Abstract][Full Text] [Related]
17. WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine.
Alzaaqi S; Naka N; Hamada K; Hosen N; Kanegae M; Outani H; Adachi M; Imanishi R; Morii E; Iwai M; Nakata J; Fujiki F; Morimoto S; Nakajima H; Nishida S; Tsuboi A; Oka Y; Sugiyama H; Oji Y
Oncol Lett; 2022 Feb; 23(2):65. PubMed ID: 35069874
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies.
Elisseeva OA; Oka Y; Tsuboi A; Ogata K; Wu F; Kim EH; Soma T; Tamaki H; Kawakami M; Oji Y; Hosen N; Kubota T; Nakagawa M; Yamagami T; Hiraoka A; Tsukaguchi M; Udaka K; Ogawa H; Kishimoto T; Nomura T; Sugiyama H
Blood; 2002 May; 99(9):3272-9. PubMed ID: 11964293
[TBL] [Abstract][Full Text] [Related]
19. [WT1 peptide cancer vaccine].
Sugiyama H
Nihon Rinsho; 2017 Feb; 75(2):263-269. PubMed ID: 30562862
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy.
Schillingmann DA; Riese SB; Vijayan V; Tischer-Zimmermann S; Schmetzer H; Maecker-Kolhoff B; Blasczyk R; Immenschuh S; Eiz-Vesper B
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
